Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 8, 2013

View Archived Issues

Tankyrase and/or Wnt signaling inhibitors designed at Novartis

Genetically engineered mouse model of pancreatic cancer developed

Shionogi reviews highlights of third quarter of fiscal 2012

Santen Pharmaceutical presents novel PARP inhibitors for ocular disorders

Microbiotix presents novel agents for bacterial infections

Eli Lilly patents new agents for sleep disorders

Mouse model allows testing of therapies targeting the human HTT gene

European decentralized registration procedure completed for BLI-800

ProtAffin Biotechnologie prepares new mutant polypeptides for cancer

Transgene divulges new mutant HBV polypeptides

Researchers at Glenmark Pharmaceuticals disclose novel monoclonal antibodies

New cholera vaccines presented by researchers in the U.S. and Bangladesh

Apocept receives FDA orphan drug designation and enters phase I study

Cerium oxide nanoparticles reduce ovarian cancer tumor growth in mice

Transgenic medaka model developed for screening drugs targeting oncogenes

Omeros reports toxicology study data for MASP-2 inhibitor

Bristol-Myers Squibb decides to stop development of analgesic

Eli Lilly discontinues clinical trials of tabalumab in RA

EMA grants accelerated assessment to trametinib application

Pergamum and Cadila Pharmaceuticals enter strategic collaboration

MSDC receives award from The Michael J. Fox Foundation

biOasis' Transcend-Herceptin conjugate shows promising antitumor activity

Dyax and CVie Therapeutics sign agreement for Kalbitor

Venaxis signs agreement with EMELCA Bioscience for E.U. launch of novel appendicitis test APPY1

Avexxin cleared to conduct study of AVX-001 in Denmark

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 10, 2025.
Corestemchemon preps US BLA filing for stem cell ALS therapy
BioWorld
Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated approval from the U.S. FDA, company...
In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol
BioWorld
In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty
BioWorld
With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...